Overall, 154 subjects completed the trial and two subjects were prematurely withdrawn before trial completion: one subject was withdrawn from reference arm night30 min by the investigator due to an adverse event suggestive of COVID-19 infection and one subject withdrew themself from treatment arm 2 hnight
Some plans may cover these injections if deemed medically necessary, while others may not
Holistic Approach : We address weight loss comprehensively, evaluating hormone balance, thyroid function, and metabolic health to tailor treatment to each patients needs
Mir-484 contributes to diminished ovarian reserve by regulating granulosa cell function via YAP1-mediated mitochondrial function and apoptosis
Although Mounjaro, Ozempic, and Rybelsus are not FDA-approved for obesity treatment, they are included in the analysis due to the high number of patients with an obesity diagnosis using these products compared to other FDA-approved diabetes GLP-1 agonists